Cyprumed GmbH

CYPRUMED® is a biopharmaceutical company developing a next generation platform technology for the oral delivery of polypeptides. The patent pending technology is entirely based on GRAS listed compounds and easy to formulate. In vivo studies with various polypeptide drugs in rodents, dogs and none human primates showed oral bioavailability up to 70% (rel. s.c.).